Word: panels
(lookup in dictionary)
(lookup stats)
Dates: during 1990-1999
Sort By: most recent first
(reverse)
...Pinochet is staying put for now. Britain's House of Lords has ordered yet another hearing after overturning a lower court ruling that would have extradited the former Chilean dictator to Spain. Pinochet's lawyers had appealed the lower court's decision because the judge on the five-person panel who cast the deciding vote is affiliated with Amnesty International, one of the prime movers in the push to bring Pinochet to trial...
...another hearing will take place to decide whether Pinochet, as a former head of state, still enjoys sovereign immunity, a British law that protects foreign dignitaries visiting England. The legal questions are complex, and how a new panel will rule is anybody's guess. "It's like replaying a football match," notes TIME London bureau chief Barry Hillenbrand. "There's no guarantee it will still turn out 3-2." Pinochet's attorneys are appealing extradition on several other fronts as well. Clearly, the only people who are guaranteed to do well in this case are Pinochet's lawyers...
Goldstein said she was also asked difficultquestions. "One of the economists on the panel,without any warning, asked me to tell him what thepartial derivative with respect to y of some longmathematical expression was--without writinganything down!" she said...
Tell that to Dr. Philip Needham, father of the cox-2 inhibitor, who calls the white paper Palmer presented to the FDA panel "a predictable effort to protect their drug." If you want evidence that Celebrex works, he says, just ask the 13,000 arthritis patients who took part in its trial. "We're getting letters saying, 'Please don't take us off,'" Needham says. And the side effects? Pretty close to placebo levels...
...Steven Abramson, chairman of the FDA advisory panel, was impressed--and not at all surprised that the big drug companies were kicking up a fuss. "The cox-2 inhibitor will make it very difficult for them to compete," he says. Which could explain why Merck, Johnson & Johnson and Glaxo Wellcome are rushing to get their own versions into trial as fast as possible...